 |
|
AIDS VaccinesAre We Ready for Human Efficacy Trials?
John R. Mascola, MD;
John G. McNeil, MD, MPH;
Donald S. Burke, MD
JAMA. 1994;272(6):488-489.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Worldwide, the human immunodeficiency virus type 1 (HIV-1) has already infected 10 million to 15 million people. With an estimated 5000 to 10 000 new infections occurring each day, 30 million to 40 million people will be infected by the year 2000.1 In developing countries, where more than 80% of new infections are occurring, the virus is predominantly transmitted heterosexually and is broadly dispersed in general populations. Vaccines that will prevent HIV-1 disease and abrogate virus transmission must be viewed as critical components of a comprehensive public health strategy designed to combat the acquired immunodeficiency syndrome (AIDS) and slow the global spread of HIV-1 infection.
See also p 475.
Although most effective viral vaccines are based on either live attenuated (eg, measles) or inactivated (eg, influenza) virus products, research strategies for HIV-1 vaccine development have focused primarily on the viral envelope glycoproteins gp 120 and gp 160. This focus
. . . [Full Text PDF of this Article]
Author Affiliations
From the Department of Infectious Diseases, Naval Medical Research Institute, Bethesda, Md (Dr Mascola), and the Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Md (Drs Mascola, McNeil, and Burke).
Footnotes
The views and positions presented in this article are those of the authors and do not purport to reflect those of the US Departments of the Army, Navy, or Defense.
Reprint requests to Walter Reed Army Institute of Research, 1600 E Gude Dr, Rockville, MD 20850 (Dr Mascola).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
